Ligand Pharmaceuticals Q2 2024 Adj. EPS $1.40 Beats $1.06 Estimate, Sales $41.531M Beat $32.865M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:27pm
Ligand Pharmaceuticals (NASDAQ:
LGND) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.06 by 32.08 percent. The company reported quarterly sales of $41.531 million which beat the analyst consensus estimate of $32.865 million by 26.37 percent. This is a 57.52 percent increase over sales of $26.366 million the same period last year.
Posted In: LGND